MX2022011472A - Formato de anticuerpo multiespecifico heterodimerico. - Google Patents
Formato de anticuerpo multiespecifico heterodimerico.Info
- Publication number
- MX2022011472A MX2022011472A MX2022011472A MX2022011472A MX2022011472A MX 2022011472 A MX2022011472 A MX 2022011472A MX 2022011472 A MX2022011472 A MX 2022011472A MX 2022011472 A MX2022011472 A MX 2022011472A MX 2022011472 A MX2022011472 A MX 2022011472A
- Authority
- MX
- Mexico
- Prior art keywords
- hetero
- specific antibody
- antibody format
- domains
- dimeric multi
- Prior art date
Links
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/626—Diabody or triabody
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención se refiere a nuevo formato multiespecífico heterodimérico de múltiples dominios variables de anticuerpos que comprenden un núcleo de dos pares de dominios variables divididos en el que tanto los dominios ligeros variables como los dos dominios pesados variables afines están situados en tándem en dos cadenas proteicas separadas, respectivamente.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP15001758 | 2015-06-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2022011472A true MX2022011472A (es) | 2023-03-01 |
Family
ID=53434175
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2017016188A MX2017016188A (es) | 2015-06-15 | 2016-06-15 | FORMATO DE ANTICUERPO MULTIESPECíFICO HETERODIMíRICO. |
MX2022011472A MX2022011472A (es) | 2015-06-15 | 2017-12-13 | Formato de anticuerpo multiespecifico heterodimerico. |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2017016188A MX2017016188A (es) | 2015-06-15 | 2016-06-15 | FORMATO DE ANTICUERPO MULTIESPECíFICO HETERODIMíRICO. |
Country Status (13)
Country | Link |
---|---|
US (2) | US11236150B2 (es) |
EP (2) | EP3307776A1 (es) |
JP (3) | JP6839101B2 (es) |
KR (1) | KR20180012860A (es) |
CN (2) | CN107922486B (es) |
AU (2) | AU2016278586B2 (es) |
CA (1) | CA2989474C (es) |
EA (1) | EA201890041A1 (es) |
HK (1) | HK1245805A1 (es) |
IL (2) | IL293435A (es) |
MA (1) | MA44381A (es) |
MX (2) | MX2017016188A (es) |
WO (1) | WO2016202457A1 (es) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3156417A1 (en) | 2015-10-13 | 2017-04-19 | Affimed GmbH | Multivalent fv antibodies |
WO2018224439A1 (en) | 2017-06-05 | 2018-12-13 | Numab Innovation Ag | Novel anti-hsa antibodies |
CA3065868C (en) | 2017-06-05 | 2024-06-04 | Numab Therapeutics AG | Novel hetero-dimeric multi-specific antibody format |
EP3634997A1 (en) | 2017-06-05 | 2020-04-15 | Numab Therapeutics AG | Novel anti-hsa antibodies |
WO2018224441A1 (en) | 2017-06-05 | 2018-12-13 | Numab Innovation Ag | Novel anti-cd3 antibodies |
EP3459968A1 (en) | 2017-09-20 | 2019-03-27 | Numab Innovation AG | Novel stable antibody variable domain framework combinations |
EP3470429A1 (en) | 2017-10-10 | 2019-04-17 | Numab Innovation AG | Antibodies targeting pdl1 and methods of use thereof |
EP3470428A1 (en) | 2017-10-10 | 2019-04-17 | Numab Innovation AG | Antibodies targeting cd137 and methods of use thereof |
EP3470426A1 (en) | 2017-10-10 | 2019-04-17 | Numab Therapeutics AG | Multispecific antibody |
SG11202002982YA (en) | 2017-10-10 | 2020-04-29 | Numab Therapeutics AG | Multispecific antibody |
CN111225926A (zh) | 2017-10-10 | 2020-06-02 | 努玛治疗有限公司 | 靶向pdl1的抗体及其使用方法 |
AU2018348431A1 (en) | 2017-10-10 | 2020-03-12 | Numab Therapeutics AG | Antibodies targeting CD137 and methods of use thereof |
CN111836630A (zh) * | 2018-01-05 | 2020-10-27 | 希望之城 | 多特异性配体结合物 |
EP3636320A1 (en) | 2018-10-09 | 2020-04-15 | Numab Therapeutics AG | Antibodies targeting cd137 and methods of use thereof |
KR20210076907A (ko) | 2018-10-09 | 2021-06-24 | 누맙 세러퓨틱스 아게 | Cd137을 표적화하는 항체 및 이의 사용 방법 |
US20220127350A1 (en) | 2019-01-31 | 2022-04-28 | Numab Therapeutics AG | Multispecific antibodies having specificity for tnfa and il-17a, antibodies targeting il-17a, and methods of use thereof |
EP3689907A1 (en) | 2019-01-31 | 2020-08-05 | Numab Therapeutics AG | Antibodies targeting il-17a and methods of use thereof |
EP3816185A1 (en) | 2019-11-04 | 2021-05-05 | Numab Therapeutics AG | Multispecific antibody directed against pd-l1 and a tumor-associated antigen |
EP3915580A1 (en) | 2020-05-29 | 2021-12-01 | Numab Therapeutics AG | Multispecific antibody |
EP4174092A4 (en) * | 2020-06-30 | 2024-03-20 | Harbour Biomed Shanghai Co Ltd | MULTI-SPECIFIC IMMUNE CELL ENGAGEMENT BINDING PROTEIN, PRODUCTION THEREOF AND USE THEREOF |
EP3988568A1 (en) | 2020-10-21 | 2022-04-27 | Numab Therapeutics AG | Combination treatment |
EP4019546A1 (en) | 2020-12-23 | 2022-06-29 | Numab Therapeutics AG | Antibody variable domains that bind il-31 |
IL303135A (en) | 2020-12-23 | 2023-07-01 | Numab Therapeutics AG | Antibody variable domains that bind IL-4R |
EP4019090A1 (en) | 2020-12-23 | 2022-06-29 | Numab Therapeutics AG | Antibody variable domains that bind il-4r |
WO2022136693A1 (en) | 2020-12-23 | 2022-06-30 | Numab Therapeutics AG | Antibody variable domains and antibodies having decreased immunogenicity |
JP2024504471A (ja) | 2021-02-02 | 2024-01-31 | ヌマブ セラピューティックス アーゲー | Ror1およびcd3に対する特異性を有する多重特異性抗体 |
CN115536749A (zh) | 2021-06-29 | 2022-12-30 | 三生国健药业(上海)股份有限公司 | 三特异性抗体、其制备方法和用途 |
EP4183800A1 (en) | 2021-11-19 | 2023-05-24 | Medizinische Hochschule Hannover | Novel sars-cov-2 neutralizing antibodies |
WO2023214047A1 (en) | 2022-05-06 | 2023-11-09 | Numab Therapeutics AG | Antibody variable domains and antibodies having decreased immunogenicity |
EP4273162A1 (en) | 2022-05-06 | 2023-11-08 | Numab Therapeutics AG | Antibody variable domains and antibodies having decreased immunogenicity |
WO2024038095A1 (en) | 2022-08-16 | 2024-02-22 | Iome Bio | NOVEL ANTI-RGMb ANTIBODIES |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE60124912T2 (de) | 2001-09-14 | 2007-06-14 | Affimed Therapeutics Ag | Multimerische, einzelkettige, Tandem-Fv-Antikörper |
EP1618181B1 (en) * | 2003-04-22 | 2014-10-15 | IBC Pharmaceuticals | Polyvalent protein complex |
WO2010132872A1 (en) * | 2009-05-15 | 2010-11-18 | Novimmune S.A | Combination therapies and methods using anti-cd3 modulating agents and anti-tnf antagonists |
RU2522002C2 (ru) | 2009-06-26 | 2014-07-10 | Ридженерон Фармасьютикалз, Инк. | Легковыделяемые биспецифические антитела с природным иммуноглобулиновым форматом |
GB201000467D0 (en) | 2010-01-12 | 2010-02-24 | Ucb Pharma Sa | Antibodies |
UY33826A (es) * | 2010-12-22 | 2012-07-31 | Abbott Lab | Proteínas de unión con dominios trivariables y sus usos |
TWI743461B (zh) | 2011-03-28 | 2021-10-21 | 法商賽諾菲公司 | 具有交叉結合區定向之雙重可變區類抗體結合蛋白 |
US20150045540A1 (en) * | 2011-06-28 | 2015-02-12 | Sea Lane Biotechnologies, Llc | Multispecific stacked variable domain binding proteins |
US20150203591A1 (en) * | 2012-08-02 | 2015-07-23 | Regeneron Pharmaceuticals, Inc. | Mutivalent antigen-binding proteins |
RU2015137858A (ru) * | 2013-02-05 | 2017-03-13 | Санофи | Иммунологическое визуализирующее средство для использования при терапии коньюгатом антитело-лекарственное средство |
CA2907597A1 (en) * | 2013-05-07 | 2014-11-13 | F. Hoffmann-La Roche Ag | Trimeric antigen binding molecules |
WO2014180577A1 (en) * | 2013-05-10 | 2014-11-13 | Numab Ag | Bispecific constructs and their use in the treatment of various diseases |
IL243311B (en) | 2013-06-26 | 2022-07-01 | Numab Therapeutics AG | New frameworks for antibodies |
EP2930188A1 (en) | 2014-04-13 | 2015-10-14 | Affimed Therapeutics AG | Trifunctional antigen-binding molecule |
EP3156417A1 (en) | 2015-10-13 | 2017-04-19 | Affimed GmbH | Multivalent fv antibodies |
-
2016
- 2016-06-15 MX MX2017016188A patent/MX2017016188A/es unknown
- 2016-06-15 EA EA201890041A patent/EA201890041A1/ru unknown
- 2016-06-15 EP EP16736380.3A patent/EP3307776A1/en active Pending
- 2016-06-15 EP EP22160481.2A patent/EP4047020A1/en active Pending
- 2016-06-15 CN CN201680048188.4A patent/CN107922486B/zh active Active
- 2016-06-15 WO PCT/EP2016/001002 patent/WO2016202457A1/en active Application Filing
- 2016-06-15 AU AU2016278586A patent/AU2016278586B2/en active Active
- 2016-06-15 KR KR1020187001156A patent/KR20180012860A/ko not_active Application Discontinuation
- 2016-06-15 CA CA2989474A patent/CA2989474C/en active Active
- 2016-06-15 CN CN202210532747.6A patent/CN115057936A/zh active Pending
- 2016-06-15 US US15/736,747 patent/US11236150B2/en active Active
- 2016-06-15 MA MA044381A patent/MA44381A/fr unknown
- 2016-06-15 JP JP2017564881A patent/JP6839101B2/ja active Active
- 2016-06-15 IL IL293435A patent/IL293435A/en unknown
-
2017
- 2017-12-13 MX MX2022011472A patent/MX2022011472A/es unknown
- 2017-12-14 IL IL256314A patent/IL256314B/en unknown
-
2018
- 2018-04-19 HK HK18105091.7A patent/HK1245805A1/zh unknown
-
2021
- 2021-02-12 JP JP2021021147A patent/JP7140861B2/ja active Active
-
2022
- 2022-01-29 US US17/588,262 patent/US11879005B2/en active Active
- 2022-08-18 AU AU2022218544A patent/AU2022218544A1/en active Pending
- 2022-09-08 JP JP2022142827A patent/JP7457764B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
WO2016202457A8 (en) | 2017-11-30 |
JP7457764B2 (ja) | 2024-03-28 |
JP2022177097A (ja) | 2022-11-30 |
MA44381A (fr) | 2019-01-23 |
IL256314A (en) | 2018-02-28 |
US11879005B2 (en) | 2024-01-23 |
US11236150B2 (en) | 2022-02-01 |
IL293435A (en) | 2022-07-01 |
US20180355024A1 (en) | 2018-12-13 |
EA201890041A1 (ru) | 2018-07-31 |
AU2016278586B2 (en) | 2022-05-19 |
CN107922486A (zh) | 2018-04-17 |
MX2017016188A (es) | 2018-07-06 |
JP2021087436A (ja) | 2021-06-10 |
WO2016202457A1 (en) | 2016-12-22 |
CN107922486B (zh) | 2022-05-31 |
AU2022218544A1 (en) | 2022-09-15 |
AU2016278586A1 (en) | 2018-01-04 |
CA2989474A1 (en) | 2016-12-22 |
JP6839101B2 (ja) | 2021-03-03 |
IL256314B (en) | 2022-06-01 |
EP3307776A1 (en) | 2018-04-18 |
HK1245805A1 (zh) | 2018-08-31 |
CA2989474C (en) | 2023-09-05 |
JP2018522545A (ja) | 2018-08-16 |
US20220332797A1 (en) | 2022-10-20 |
JP7140861B2 (ja) | 2022-09-21 |
KR20180012860A (ko) | 2018-02-06 |
CN115057936A (zh) | 2022-09-16 |
EP4047020A1 (en) | 2022-08-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2022011472A (es) | Formato de anticuerpo multiespecifico heterodimerico. | |
MX2021006237A (es) | Anticuerpos anti-tigit, anticuerpos anti-pvrig y combinaciones de estos. | |
EP3461261A4 (en) | PROTEINS BINDING TO THE VARIABLE MONOCATERARY FRAGMENT OF CD3 | |
PH12017502180A1 (en) | Tau-binding antibodies | |
EP3416690A4 (en) | SPECIFIC APTAMER | |
EA201791562A1 (ru) | Антигены цитомегаловируса и их применения | |
PH12017502207A1 (en) | Tau-binding antibodies | |
DK3142750T3 (da) | Sammensætninger omfattende aav, som udtrykker dobbelt-antistofkonstrukter og anvendelser deraf | |
IL280004A (en) | Antibody molecules that bind PD-L1 and CD137 | |
ZA201803681B (en) | Multi-specific antibody molecules having specificity for tnf-alpha, il-17a and il-17f | |
IL254239A0 (en) | Modified antibodies that bind to transforming growth factor-beta-1 with high affinity, avidity and specificity | |
EP3689903A4 (en) | FIBRONECTIN B DOMAIN BINDING PROTEIN | |
EP3807318A4 (en) | MULTISPECIFIC ANTIBODY CONSTRUCTS | |
EP3554535A4 (en) | PD-L1 BINDING FIBRONECTIN TYPE III DOMAINS | |
IL254238A0 (en) | ß1 transforming growth factor binding dimers with high affinity, avidity and specificity | |
EP3368900A4 (en) | Sandwich assay for small molecules | |
NZ731491A (en) | Cd83 binding proteins and uses thereof | |
EP3464598A4 (en) | APTAMER-BASED ANALYTICAL TESTS | |
EP3309169A4 (en) | Antibody binding specifically to isolated vimentin-derived peptide, or binding fragment of the peptide | |
EP3660155A4 (en) | ANTI-CD147 ANTIBODY | |
EP3444273A4 (en) | ANTIBODY BINDING SPECIFICALLY TO AIMP2-DX2 PROTEIN | |
EP3243837A4 (en) | Bispecific antibody binding to trailr2 and psma | |
IL292799A (en) | Antibodies against siglec-9 | |
EP3583134A4 (en) | NEW MULTI-SPECIFIC BINDING PROTEINS | |
GB201818283D0 (en) | Antibody molecules that bind PD-L1 and CD137 |